Genetic Tests Come Under Scrutiny in Trump Administration’s Fraud Crackdown

Why It Matters

Targeted anti‑fraud measures could protect billions in Medicare funds while shaping the regulatory landscape for emerging precision diagnostics.

Key Takeaways

• Genetic tests 43% Medicare lab spend, 5% of tests
• CMS seeks new authority to curb lab test fraud
• MolDX program may become mandatory for Medicare coverage
• Fraud schemes have billed over $3 billion to Medicare
• Stricter rules could deter innovation in diagnostic testing

Pulse Analysis

The surge in genomic and molecular diagnostics has outpaced traditional oversight mechanisms, creating fertile ground for sophisticated fraud schemes that siphon billions from Medicare. By issuing an RFI, CMS signals a shift toward data‑driven enforcement, inviting stakeholders to propose analytics, statutory amendments, and procedural safeguards. This proactive stance reflects broader federal concerns about the disproportionate cost share of genetic tests, which now dominate lab expenditures despite their modest volume, underscoring the urgency of precise detection tools.

Industry reaction centers on the potential expansion of the MolDX program, a Medicare contractor‑run framework that standardizes coverage policies across 28 states. A mandatory MolDX registration could streamline fraud monitoring but also impose additional administrative burdens on labs operating on thin margins. Trade groups like the American Clinical Laboratory Association advocate for evidence‑based rules that preserve patient access while deterring bad actors, highlighting the delicate balance between regulatory rigor and fostering innovation in personalized medicine.

The broader market implications extend beyond Medicare. As private insurers and Medicare Advantage plans mirror federal policies, heightened anti‑fraud regulations could reshape reimbursement models and investment decisions across the diagnostic sector. Companies may prioritize compliance infrastructure, potentially slowing the rollout of novel tests. However, clearer guidelines could also level the playing field, rewarding legitimate providers and restoring confidence among patients and payers. Navigating this evolving landscape will require collaborative policy design, robust data analytics, and vigilant oversight to protect both fiscal integrity and the promise of precision health.